Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone for LVH in Dialysis Patients
NCT01128101Phase 4Unknown
- Sponsor
- Hospital das Clínicas da Faculdade de Medicina de Botucatu
- Start
- Mar 2011
- Primary completion
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in left ventricular hypertrophy (LVH) comparing Spironolactone with Placebo (2 arms). Primary endpoint: Reduction of Left Ventricular Hypertrophy at 12 months. Status: unknown.
02
Drugs
spironolactone
03
Conditions
left ventricular hypertrophy (LVH)
Beyond the preview
Go deeper on NCT01128101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01128101.